港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

长春高新技术产业(集团)股份有限公司（临时代码）

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

市销率: - -

数据加载中...

总览公司新闻资讯公告

长春高新也老树开花了

长春高新(000661.SZ)子公司两款药品新纳入国家医保目录

长春高新(000661.SZ)：GenSci142胶囊境内生产药品注册临床试验申请获批准

“东北药茅”长春高新拟赴港上市证监会就募资用途等问题要求补充说明

红星资本局

新股消息 | 长春高新(000661.SZ)拟港股上市中国证监会要求补充说明募集资金用途等

长春高新：港交所审批后续需获证监会备案并通过联交所聆讯

长春高新(000661.SZ)：GenSci134注射液境内生产药品注册临床试验申请获批准

葵花药业收警示函，达嘉维康副总经理辞职，长春高新1类新药获批临床，贝达药业与晟斯生物达成战略合作

长春高新：金蓓欣2025年6月底获批后，7月中旬开始上市销售，目前销售情况良好

长春高新(000661.SZ)发布前三季度业绩，归母净利润11.65亿元，同比下降58.23%

长春高新大变局，谁“挤压”了利润？

长春高新(000661.SZ)：注射用GenSci139境内生产药品临床试验获批

净利润暴跌42%、三费高企46%！长春高新赴港上市难掩“内忧外患”

长春高新(000661.SZ)：注射用GenSci143临床试验申请获受理

昔日超级大牛股长春高新，拟赴港上市！

九成收入依赖六款产品，集采后业绩暴跌，“东北药茅”长春高新启动“A+H”计划

长春高新(000661.SZ)子公司三价流感病毒裂解疫苗(BK-01佐剂)临床试验申请获批准

“东北药茅”长春高新申请赴港上市，业绩滑坡、市值缩水超1600亿元

《理财周刊》

长春高新押注脱敏市场求解背后：集采压价与竞争加剧成掣肘

天坛生物高管辞职，长春高新拟赴港上市，恒瑞医药1类新药获批临床，罗欣药业拟定增募资8.42亿元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/91272/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"91272","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91272\",,,,,undefined,":{"symbol":"91272","market":"HK","secType":"STK","nameCN":"长春高新技术产业(集团)股份有限公司（临时代码）","latestPrice":0,"timestamp":0,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"03-25 14:51:30","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774426200000},"marketStatusCode":2,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1774402200000,1774411200000],[1774414800000,1774425600000]],"volumeRatio":0,"lotSize":0,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91272\",,,,,undefined,":{"symbol":"91272","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91272\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91272\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91272\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91272\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592967064","title":"长春高新也老树开花了","url":"https://stock-news.laohu8.com/highlight/detail?id=2592967064","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592967064?lang=zh_cn&edition=fundamental","pubTime":"2025-12-17 09:37","pubTimestamp":1765935472,"startTime":"0","endTime":"0","summary":"12月15日，长春高新宣布控股子公司长春金赛药业授权其下属全资子公司——上海赛增医疗科技有限公司作为技术许可方，与被许可方Yarrow Bioscience,Inc.签订GenSci098注射液项目独家许可协议。近期开发里程碑款项：预计交付相关临床研究报告及数据等资料后向赛增医疗支付5000万美元。赛增医疗将在后续产品上市后有权获得超过净销售额10%的销售提成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217093755a4548e4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217093755a4548e4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","02196","91272","BK1515"],"gpt_icon":0},{"id":"2589337793","title":"长春高新(000661.SZ)子公司两款药品新纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337793","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589337793?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 16:54","pubTimestamp":1765184075,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，据国家医疗保障局及人力资源社会保障部发布的《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》，公司控股子公司长春金赛药业有限责任公司(简称“金赛药业”)自主研发的金赛增(现通用名为“金培生长激素注射液”)、合作引进的美适亚(通用名为“醋酸甲地孕酮口服混悬液”)均被新纳入国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91272","BK0046","BK0075","000661","BK0028","BK0057","BK0188","BK0239"],"gpt_icon":0},{"id":"2586546243","title":"长春高新(000661.SZ)：GenSci142胶囊境内生产药品注册临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2586546243","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586546243?lang=zh_cn&edition=fundamental","pubTime":"2025-11-27 16:55","pubTimestamp":1764233713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci142胶囊注册临床试验申请获得批准。据悉，GenSci142胶囊是金赛药业开发的一款1类创新生物制品，拟用于细菌性阴道病的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0046","91272","BK0075","BK0028","BK0057","BK0239","BK0188"],"gpt_icon":0},{"id":"2584606794","title":"“东北药茅”长春高新拟赴港上市 证监会就募资用途等问题要求补充说明","url":"https://stock-news.laohu8.com/highlight/detail?id=2584606794","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584606794?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 22:35","pubTimestamp":1763390100,"startTime":"0","endTime":"0","summary":"　　11月17日消息，在9月底递表港交所后，“生长激素一哥”长春高新 近日收到证监会境外发行上市备案补充材料要求。　　11月14日，证监会共对10家拟港股上市企业出具补充材料要求。其中，证监会就长春高新募集资金用途、下属子公司开展相关业务及具体运营情况等问题要求长春高新进行补充说明。然而，也因为过度依赖生长激素业务，且公司带状疱疹疫苗遭遇挫折，2024年及2025年上半年，长春高新营收、净利润双双出现下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-17/doc-infxtqvw4711065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91272","BK0057","BK0239","BK0075","BK0188","BK0046","BK0028","000661"],"gpt_icon":0},{"id":"2583508022","title":"新股消息 | 长春高新(000661.SZ)拟港股上市 中国证监会要求补充说明募集资金用途等","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508022","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508022?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 19:48","pubTimestamp":1763120916,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月14日，中国证监会公布《境外发行上市备案补充材料要求》。中国证监会国际司公示10家企业补充材料要求，其中，公示提到要求长春高新补充说明公司募集资金用途、以及业务涉及AI大模型的具体情况等。据港交所9月29日披露，长春高新技术产业(集团)股份有限公司向港交所主板提交上市申请书，中信建投国际为其独家保荐人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0075","BK0046","BK0028","91272","000661","BK0239","BK0057","BK0188"],"gpt_icon":0},{"id":"2581662068","title":"长春高新：港交所审批后续需获证监会备案并通过联交所聆讯","url":"https://stock-news.laohu8.com/highlight/detail?id=2581662068","media":"新浪财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581662068?lang=zh_cn&edition=fundamental","pubTime":"2025-11-06 17:00","pubTimestamp":1762419600,"startTime":"0","endTime":"0","summary":"投资者提问：谢谢回复！请问港交所的审批流程是怎样的？能具体介绍一下吗？谢谢！董秘回答(长春高新SZ000661)：您好，对于公司来说，后续需要取得中国证监会的备案并需通过联交所聆讯，谢谢！查看更多董秘问答>>免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确性，内容仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106172631a6e58e29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106172631a6e58e29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B3T34201.USD","LU1023057109.AUD","LU0197773673.USD","LU0417516902.SGD","LU0651946864.USD","LU1048596156.SGD","LU1282649141.HKD","LU0651947912.USD","LU0797268264.HKD","LU0197773160.USD","LU0821914370.USD","LU1051768304.USD","LU1242518857.USD","LU1734074674.USD","LU0918141887.USD","LU0819123356.HKD","00388","91272","LU0594300419.USD","80388","LU0048597586.USD","LU0320764599.SGD","LU1642822792.SGD","LU1993786604.SGD","LU1481107354.HKD","LU1981816686.USD","LU0261947096.USD","LU0417516738.SGD","LU0359202008.SGD","LU1226287529.USD","LU1366334651.USD","LU0516423091.SGD","LU0348825331.USD","LU1211504680.USD","SG9999001051.SGD","LU0819121731.USD","LU1282648689.USD","LU0084288322.USD","BK1610","LU0516422440.USD","LU1807302812.USD","LU1515016050.SGD","LU0708995583.HKD","HKXCY","HEXmain","LU1051769294.HKD","LU0456846285.SGD","LU0106959298.USD","LU0918141705.HKD","LU0370786039.SGD"],"gpt_icon":0},{"id":"2580291336","title":"长春高新(000661.SZ)：GenSci134注射液境内生产药品注册临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2580291336","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580291336?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 19:00","pubTimestamp":1762167629,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci134注射液的境内生产药品注册临床试验申请获得批准。公告显示，GenSci134注射液是金赛药业自主研发的一款治疗用生物制品1类药物，拟用于生长激素缺乏症(GHD)包括成人生长激素缺乏症(AGHD)、儿童生长激素缺乏症(PGHD)和非GHD(包括ISS等)患者的治疗。本次申请针对的是特发性身材矮小(ISS)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","91272","BK0057","BK0075","BK0239","BK0188","BK0046","BK0028"],"gpt_icon":0},{"id":"2580237622","title":"葵花药业收警示函，达嘉维康副总经理辞职，长春高新1类新药获批临床，贝达药业与晟斯生物达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2580237622","media":"谈医说药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580237622?lang=zh_cn&edition=fundamental","pubTime":"2025-11-02 22:49","pubTimestamp":1762094989,"startTime":"0","endTime":"0","summary":"长春高新：公司子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci134注射液的境内生产药品注册临床试验申请获得批准。相关数据显示，左卡尼汀注射液2024年度中国院内市场规模为1.03亿支，销售金额为9.65亿元。截至公告披露日，左卡尼汀注射液累计投入的研发费用为376万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251102225411a483022f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251102225411a483022f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91287","BK1161","06628","91272"],"gpt_icon":0},{"id":"2579245942","title":"长春高新：金蓓欣2025年6月底获批后，7月中旬开始上市销售，目前销售情况良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2579245942","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579245942?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 16:37","pubTimestamp":1761899820,"startTime":"0","endTime":"0","summary":"证券日报网讯长春高新10月31日发布公告，在公司回答调研者提问时表示，金蓓欣2025年6月底获批后，7月中旬开始上市销售，目前销售情况良好，2025年第三季度已经实现销售收入超过5500万元。公司目前已搭建两百余人的销售团队，也在迅速提升医院、渠道等覆盖率。后续，公司将进一步集中资源，重点推进相关具备较高市场潜力的重点新产品，努力推动相关新业务成为公司新的业绩增长点，进一步推进公司多元化转型升级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-31/doc-infvupap8703462.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-31/doc-infvupap8703462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0046","BK0239","BK0075","000661","BK0188","BK0057","91272"],"gpt_icon":0},{"id":"2579121279","title":"长春高新(000661.SZ)发布前三季度业绩，归母净利润11.65亿元，同比下降58.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579121279","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579121279?lang=zh_cn&edition=fundamental","pubTime":"2025-10-30 23:40","pubTimestamp":1761838825,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布2025年三季度报告，前三季度，公司实现营业收入98.07亿元，同比下降5.60%。归属于上市公司股东的净利润11.65亿元，同比下降58.23%。归属于上市公司股东的扣除非经常性损益的净利润12.69亿元，同比下降55.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91272","000661"],"gpt_icon":0},{"id":"2577328271","title":"长春高新大变局，谁“挤压”了利润？","url":"https://stock-news.laohu8.com/highlight/detail?id=2577328271","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577328271?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 11:37","pubTimestamp":1761190620,"startTime":"0","endTime":"0","summary":"文｜《投资者网》蔡俊近期，长春高新正式向港交所递交主板上市申请。截至目前，公司市值约500亿元左右。早前，公司的首次尝试未能收效，其化整为零的路径造成净利率明显下滑。随后，公司表示经营情况一切正常。公司在相关财报中，也把净利润的降速归于组织架构重设引发的费用调整、增长。公司表示，内部重构期间相关费用在会计处理方面较以前年度有所变化。两端挤压下，造成公司净利率急速下滑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1761101836256082424","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["91272"],"gpt_icon":0},{"id":"2576853538","title":"长春高新(000661.SZ)：注射用GenSci139境内生产药品临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2576853538","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576853538?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 18:50","pubTimestamp":1760957414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司子公司——长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意注射用GenSci139单药在晚期实体瘤患者中开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","91272","BK0188","000661","BK0075","BK0028","BK0057","BK0046"],"gpt_icon":0},{"id":"2576888708","title":"净利润暴跌42%、三费高企46%！长春高新赴港上市难掩“内忧外患”","url":"https://stock-news.laohu8.com/highlight/detail?id=2576888708","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576888708?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 08:25","pubTimestamp":1760919900,"startTime":"0","endTime":"0","summary":"　　当“东北药茅”长春高新的港股招股书在香港交易所披露易网站亮相时，市场并未给出期待中的积极反馈。近三十年A股上市历程中积累的光环，正被生长激素红利消退后的阴影逐渐吞噬，赴港上市能否成为破局关键，眼下仍是未知数。　　对于长春高新而言，赴港上市或许能缓解短期资金压力，但无法解决核心的业务困境。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-20/doc-infunxxn8395562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000661","91272"],"gpt_icon":0},{"id":"2576087581","title":"长春高新(000661.SZ)：注射用GenSci143临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2576087581","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576087581?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 16:51","pubTimestamp":1760691086,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司子公司——长春金赛药业有限责任公司(“金赛药业”)收到美国食品药品监督管理局(“FDA”)书面通知，金赛药业注射用GenSci143临床试验申请获得受理，适应症为：晚期实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0075","BK0188","BK0046","BK0028","91272","BK0239","000661","BK0057"],"gpt_icon":0},{"id":"2575785893","title":"昔日超级大牛股长春高新，拟赴港上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2575785893","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575785893?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 18:23","pubTimestamp":1760523780,"startTime":"0","endTime":"0","summary":"　　昔日超级大牛股，拟赴港上市！　　曾经的超级大牛股长春高新，近日向香港联交所递交了境外上市（H股）申请。　　自2021年至今，长春高新股价持续下滑，至今跌幅超过70%。　　长春高新销售药品的毛利率从2022年的91.6%，持续下滑至2025年上半年的88.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-10-15/doc-inftymnk1982277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91272","BK0057","BK0075","000661","BK0239","BK0188","BK0046","BK0028"],"gpt_icon":0},{"id":"2575294649","title":"九成收入依赖六款产品，集采后业绩暴跌，“东北药茅”长春高新启动“A+H”计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2575294649","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575294649?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 19:13","pubTimestamp":1760440436,"startTime":"0","endTime":"0","summary":"而随着生长激素被纳入集采范围，核心产品价格直线下滑，如今的长春高新业绩近乎腰斩。除了赖以生存的生长激素暴跌外，长春高新的第二增长曲线疫苗业务也遭遇挫折。因此，目前长春高新的资金流动性良好，2025年上半年，公司经营现金流净额为12.21亿元。截至2025年上半年末，长春高新货币资金达43.65亿元，交易性金融资产16.41亿元，两项合计60.06亿元，而短期借款和一年内到期流动负债合计仅4.01亿元。因此，近年来长春高新在研发投入方面十分慷慨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1760439333904059129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["91272"],"gpt_icon":0},{"id":"2575408565","title":"长春高新(000661.SZ)子公司三价流感病毒裂解疫苗(BK-01佐剂)临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2575408565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575408565?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 19:11","pubTimestamp":1760353889,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司子公司百克生物收到国家药品监督管理局对其三价流感病毒裂解疫苗(BK-01佐剂)下发的《药物临床试验批准通知书》，同意开展预防疫苗相关型别流感病毒引起的流行性感冒的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","LU0477156953.USD","LU0130517989.USD","BK4135","LU0980610538.SGD","000661","BK0075","BK0057","LU0130102774.USD","BK0239","LU0648001328.SGD","BK0188","BK4585","BK4559","LU1201861249.SGD","159646","LU1699723380.USD","LU1571399168.USD","BK0028","91272","BK4588","BK"],"gpt_icon":0},{"id":"2574455073","title":"“东北药茅”长春高新申请赴港上市，业绩滑坡、市值缩水超1600亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574455073","media":"《理财周刊》","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574455073?lang=zh_cn&edition=fundamental","pubTime":"2025-10-11 20:38","pubTimestamp":1760186280,"startTime":"0","endTime":"0","summary":"子公司金赛药业作为公司的“现金奶牛”，贡献长春高新近80%的营收，但其2024年收入下降3.73%，净利润下滑40.67%。市场竞争方面，长春高新面临前所未有的压力。长春高新解释称，这是由于“金赛药业新BU管理架构的调整及相关下一级子公司的设立”导致的。长春高新在财报中披露了体重控制品牌赛必健，包括胃内占容食品、运动营养食品等产品。在此背景下，长春高新赴港上市的战略意义不言而喻。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-11/doc-inftprki4820866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91272","BK0075","BK0028","BK0239","BK0188","BK0057","000661","BK0046"],"gpt_icon":0},{"id":"2573946610","title":"长春高新押注脱敏市场求解背后：集采压价与竞争加剧成掣肘","url":"https://stock-news.laohu8.com/highlight/detail?id=2573946610","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573946610?lang=zh_cn&edition=fundamental","pubTime":"2025-10-08 16:06","pubTimestamp":1759910760,"startTime":"0","endTime":"0","summary":"　　有着“东北药茅”之称的长春高新，今年上半年延续去年业绩营利双降的业绩颓势。　　证券之星注意到，金赛药业依靠生长激素产品，曾年销售额一度超百亿元。但随着竞争加剧、集采压价，金赛药业业绩已难增长。　　切入脱敏治疗赛道，可以视为长春高新谋变的之举。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-10-08/doc-inftepri0325843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91272","BK0046","BK0075","000661","BK0028","BK0057","BK0188","BK0239"],"gpt_icon":0},{"id":"2571694643","title":"天坛生物高管辞职，长春高新拟赴港上市，恒瑞医药1类新药获批临床，罗欣药业拟定增募资8.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2571694643","media":"谈医说药","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571694643?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 23:48","pubTimestamp":1759160919,"startTime":"0","endTime":"0","summary":"博瑞医药：公司获美国FDA批准开展BGM1812注射液用于超重或肥胖治疗的I期临床。公司于2024年5月13日获得申报受理通知书，并于近日获得国家药监局批准。截至公告日，公司就该药品累计研发投入为843.59万元人民币。该药品为治疗晚期恶性实体肿瘤的基因治疗药物，目前全球共有5个溶瘤病毒药物获得审批上市，国内市场约7个药物处于I/II期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930011418a6a6ba5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930011418a6a6ba5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU0359201885.HKD","LU1023057109.AUD","LU2543165471.USD","LU0359202008.SGD","08058","BK1191","91272","LU0359201612.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}